Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22634192 | 0.96 | KIF11 (0.48) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL367485 | 0.96 | KIF11 (0.48) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL367484 | 0.96 | KIF11 (0.48) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL29422004 | 0.92 | MMP2 (0.52) | KIF11MMP2MMP9TLR2FOLH1 | |
| SCHEMBL7593135 | 0.88 | MMP9 (0.47) | MMP2MMP9TLR2FOLH1CA1 | |
| SCHEMBL17274480 | 0.86 | KIF11 (0.50) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL7603846 | 0.86 | KIF11 (0.50) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL25184422 | 0.85 | MMP2 (0.44) | KIF11MMP2MMP9TLR2FOLH1 | |
| SCHEMBL31453869 | 0.84 | KIF11 (0.52) | KIF11MMP2MMP9TLR2 | |
| SCHEMBL6137131 | 0.80 | KIF11 (0.47) | KIF11CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256532-B | RGD cyclopeptide synthesis method | 湖北强耀生物科技有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-119504502-A | Fmoc-Lys (Mtt) -OH preparation method | 四川什邡市三高生化实业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4504342-A1 | BIFUNCTIONAL PEPTIDE WITH MUCOADHESIVE AND VIRUS BINDING PROPERTIES | Freie Universität Berlin (DE) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023187142-A1 | BIFUNCTIONAL PEPTIDE WITH MUCOADHESIVE AND VIRUS BINDING PROPERTIES | FREIE UNIVERSITÄT BERLIN (DE) | 2023-10-05 | — | — | WO | disclosed |
| CN-116390938-A | Exendin-4 analogues | TXP制药股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4196495-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP Pharma GmbH (CH) | 2023-06-21 | — | — | EP | disclosed |
| CN-110256532-B | RGD cyclopeptide synthesis method | 湖北强耀生物科技有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-110256532-B | RGD cyclopeptide synthesis method | 湖北强耀生物科技有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220315631-A1 | STAPLED BETA-CATENIN LIGANDS | OHIO STATE INNOVATION FOUNDATION | 2022-10-06 | — | — | US | disclosed |
| EP-4021473-A1 | STAPLED BETA-CATENIN LIGANDS | Ohio State Innovation Foundation (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022034062-A1 | EXENDIN-4 PEPTIDE ANALOGUES | TXP PHARMA AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| WO-2021041895-A1 | STAPLED BETA-CATENIN LIGANDS | OHIO STATE INNOVATION FOUNDATION (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2018232491-A1 | MITOCHONDRIAL TARGETED RELEASABLE LINKER | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2018-12-27 | — | — | WO | disclosed |
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |
| US-20060263303-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO INTERNATIONAL BV (NL) | 2006-11-23 | — | — | US | disclosed |
| US-20060258566-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO INTERNATIONAL BV (NL) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315631-A1 | STAPLED BETA-CATENIN LIGANDS | CTNNB1, CTNNBL1, CTNND1 | KIF11 3031/4885MMP2 660/4885MMP9 1164/4885 |
| US-20060263303-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | KIF11 1738/4885MMP2 2253/4885MMP9 2225/4885 |
| US-20060258566-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | KIF11 1738/4885MMP2 2253/4885MMP9 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.